BR112012028592A2 - método para fabricação de uma composição de glicosaminoglicano, composição de glicosaminoglicano, seus usos e preparação adequada para aplicação à pele ou membrana mucosa - Google Patents

método para fabricação de uma composição de glicosaminoglicano, composição de glicosaminoglicano, seus usos e preparação adequada para aplicação à pele ou membrana mucosa

Info

Publication number
BR112012028592A2
BR112012028592A2 BR112012028592A BR112012028592A BR112012028592A2 BR 112012028592 A2 BR112012028592 A2 BR 112012028592A2 BR 112012028592 A BR112012028592 A BR 112012028592A BR 112012028592 A BR112012028592 A BR 112012028592A BR 112012028592 A2 BR112012028592 A2 BR 112012028592A2
Authority
BR
Brazil
Prior art keywords
glycosaminoglycan composition
skin
manufacture
application
mucous membrane
Prior art date
Application number
BR112012028592A
Other languages
English (en)
Portuguese (pt)
Inventor
Turley Eva
Original Assignee
London Health Science Centre Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by London Health Science Centre Res Inc filed Critical London Health Science Centre Res Inc
Publication of BR112012028592A2 publication Critical patent/BR112012028592A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01212—Hyaluronan synthase (2.4.1.212)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
BR112012028592A 2010-05-10 2011-05-04 método para fabricação de uma composição de glicosaminoglicano, composição de glicosaminoglicano, seus usos e preparação adequada para aplicação à pele ou membrana mucosa BR112012028592A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2703532A CA2703532C (en) 2010-05-10 2010-05-10 Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications
PCT/CA2011/000512 WO2011140630A1 (en) 2010-05-10 2011-05-04 Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications

Publications (1)

Publication Number Publication Date
BR112012028592A2 true BR112012028592A2 (pt) 2018-05-08

Family

ID=44912981

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012028592A BR112012028592A2 (pt) 2010-05-10 2011-05-04 método para fabricação de uma composição de glicosaminoglicano, composição de glicosaminoglicano, seus usos e preparação adequada para aplicação à pele ou membrana mucosa

Country Status (10)

Country Link
US (2) US20130059769A1 (enExample)
EP (1) EP2569364B1 (enExample)
JP (1) JP6120283B2 (enExample)
KR (1) KR101831215B1 (enExample)
CN (2) CN107814853A (enExample)
AU (1) AU2011252695B2 (enExample)
BR (1) BR112012028592A2 (enExample)
CA (1) CA2703532C (enExample)
RU (1) RU2637443C2 (enExample)
WO (1) WO2011140630A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014001148A (ja) * 2012-06-15 2014-01-09 Picaso Cosmetic Laboratory Ltd 線維芽細胞増殖促進剤
ITMI20130354A1 (it) 2013-03-08 2014-09-09 Again Life Italia Srl Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie.
WO2014165713A2 (en) * 2013-04-03 2014-10-09 Cedars-Sinai Medical Center Treatment of inflammatory conditions by modulation of hyaluronan and hyaluronidase activity
WO2017180788A1 (en) * 2016-04-12 2017-10-19 Illustris Pharmaceuticals, Inc. Compositions for topical application of compounds
ES2989582T3 (es) 2018-05-03 2024-11-27 Collplant Ltd Rellenos dérmicos y aplicaciones de los mismos
US20210000910A1 (en) 2019-07-03 2021-01-07 Jysk Skin Solutions Pte Ltd Topical compositions
CN110339223A (zh) * 2019-08-06 2019-10-18 无锡市新吴区新安街道社区卫生服务中心 一种缓解颈椎病症状的喷雾剂制备方法
US20210106506A1 (en) * 2019-10-11 2021-04-15 Elc Management Llc Methods for cosmetic skin remodeling
CN110755597B (zh) * 2019-10-24 2023-07-07 广州市希丽生物科技服务有限公司 用于预防和治疗类风湿性关节炎的外用药物组合物
CN111249472B (zh) * 2020-01-16 2024-02-23 上海交通大学医学院附属第九人民医院 一种可经皮给药的透明质酸纳米凝胶及其制备方法
CN111166692A (zh) * 2020-03-18 2020-05-19 深圳市百吉因生物科技有限公司 一种高保湿性组合物
KR102583416B1 (ko) * 2020-04-14 2023-10-04 코스맥스 주식회사 저분자 콜라겐, 엘라스틴 및 글리코사미노글리칸을 포함하는 화장료 조성물
KR20230133305A (ko) 2021-01-29 2023-09-19 가부시키가이샤 코세 세라마이드류 함유 조성물
US12083204B2 (en) 2022-06-02 2024-09-10 L'oreal Topical composition for homeostatic delivery of nitric oxide and uses thereof
CN117137830B (zh) * 2023-11-01 2024-02-13 杭州湃肽生化科技有限公司 一种皮肤修复组合物及其应用
CN120168654A (zh) * 2025-05-21 2025-06-20 长春赛诺美焱科技有限公司 一种透皮递送耦合物、缓释透皮制剂及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4009282A (en) * 1973-12-17 1977-02-22 The Regents Of The University Of Michigan Treatment of proliferating skin diseases with prostaglandins
JP2997018B2 (ja) * 1990-07-24 2000-01-11 生化学工業株式会社 燐脂質又は脂質結合グリコサミノグリカン
US5733892A (en) * 1990-07-24 1998-03-31 Seikagaku Corporation Metastasis inhibitor composition comprising a phospholipid-linked glycosaminoglycan and method for inhibiting metastasis employing the same
US5464942A (en) * 1990-07-24 1995-11-07 Seikagaku Kogyo Kabushiki Kaisha Phospholipid- or lipid-linked glycosaminoglycan and process for producing the same
JP3714683B2 (ja) * 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
JP3615346B2 (ja) * 1997-02-18 2005-02-02 株式会社ノエビア 皮膚外用剤
JP3032824B1 (ja) * 1999-01-28 2000-04-17 東京医科歯科大学長 骨誘導促進剤
US7393938B2 (en) * 2000-01-10 2008-07-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US20060189569A1 (en) * 2000-01-10 2006-08-24 Saul Yedgar Use of lipid conjugates in the treatment of infection
JP4876334B2 (ja) * 2001-06-06 2012-02-15 日油株式会社 ヒアルロン酸産生能増強剤およびその用途
ES2607802T3 (es) * 2001-08-14 2017-04-04 Tel Aviv University Future Technology Development L.P. Partículas lipidadas de glicosaminoglicano y su uso en el suministro de fármacos y genes para diagnóstico y terapia
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
EP2434282A3 (en) * 2002-07-01 2012-08-22 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
EP1681306B1 (en) * 2003-10-29 2013-02-20 Teijin Limited Hyaluronic acid compound, hydrogel thereof and material for treating joint
JP2008519076A (ja) * 2004-11-02 2008-06-05 テルアビブ ユニバーシティ フューチャー テクノロジー デベロップメント エル．ピー． 脂質化グリコサミノグリカン粒子中の水不溶性又は水難溶性薬物の処方、並びに診断及び治療のためのこれらの使用
JP4832007B2 (ja) 2005-06-13 2011-12-07 帝人株式会社 グリコサミノグリカン誘導体の製造法
CN1742623A (zh) * 2005-07-13 2006-03-08 凌沛学 透明质酸磷脂复合物及其制备方法
ES2616295T3 (es) * 2005-10-12 2017-06-12 Seikagaku Corporation Agente para aplicar a mucosa y procedimiento para la producción del mismo
US20080183282A1 (en) * 2006-03-09 2008-07-31 Saul Yedgar Use of lipid conjugates for the coating of stents and catheters
DE102007028360B4 (de) * 2007-06-15 2016-04-14 Marcus Asam Wirkstoffkombination für kosmetische Zubereitungen
EP2222270B1 (en) * 2007-12-26 2018-11-14 Mark A. Pinsky Collagen formulations for improved skin care
EP2259775B1 (en) * 2008-02-27 2015-07-22 Ramot at Tel-Aviv University Ltd. System for delivery of protein in insoluble fibrillar form

Also Published As

Publication number Publication date
CN103080204A (zh) 2013-05-01
EP2569364B1 (en) 2018-06-13
CN107814853A (zh) 2018-03-20
CN103080204B (zh) 2017-12-12
RU2012152562A (ru) 2014-06-20
EP2569364A4 (en) 2013-10-02
JP6120283B2 (ja) 2017-04-26
WO2011140630A1 (en) 2011-11-17
RU2637443C2 (ru) 2017-12-04
AU2011252695A1 (en) 2013-01-10
US20150368373A1 (en) 2015-12-24
CA2703532A1 (en) 2011-11-10
KR101831215B1 (ko) 2018-04-04
US20130059769A1 (en) 2013-03-07
EP2569364A1 (en) 2013-03-20
KR20130113325A (ko) 2013-10-15
AU2011252695B2 (en) 2016-04-21
CA2703532C (en) 2018-05-01
US10131717B2 (en) 2018-11-20
JP2013526620A (ja) 2013-06-24

Similar Documents

Publication Publication Date Title
BR112012028592A2 (pt) método para fabricação de uma composição de glicosaminoglicano, composição de glicosaminoglicano, seus usos e preparação adequada para aplicação à pele ou membrana mucosa
BR112012029746A2 (pt) composição para tratamento da pele, método para fornecer um efeito microbicida para pele e uso de uma combinação
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
BR112012023264A8 (pt) método para alterar a composição dos ácidos graxos da membrana cerebral, método para aperfeiçoar o desempenho cognitivo em um indivíduo humano e uso de uma composição
BR112013015859A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica
BR112013011730A2 (pt) composição de oligossacarídeos para tratar doenças da pele
CR20120596A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BR112014019233A2 (pt) emplastros medicinais para criar ou manter uma área de tecido humano livre de contaminantes
BRPI0923589A2 (pt) uso de uma composição espumável essencialmente livre de ingredientes farmaceuticamente ativos para o tratamento da pele humana.
BR112013009142A2 (pt) "composição modeladora de fibra queratinosa, kit modelador de fibra queratinosa e métod para tratamento de uma fibra queratinosa"
BR112014010186A2 (pt) formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal
CL2012003290A1 (es) Metodo para preparar una composicion enriquecida en igg a partir de plasma; composicion acuosa de igg; composicion farmaceutica que comprende dicha composicion acuosa; uso de dicha composicion para tratar enfermedad autoinmune o infeccion aguda
SV2011004019A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
BRPI1013640A2 (pt) composicao farmaceutica, metodos para o tratamento e usos dos mesmos
BR112013015855A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
PT2613798E (pt) Utilização de lipase ácida lisossomal para o tratamento da deficiência de lipase ácida lisossomal em doentes
BRPI0916456A2 (pt) composto e composição lipídicos e respectivos métodos de produção e usos (incluindo método de tratamento e de prevenção de doenças que utilizam os mesmos)
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
FI20135146L (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
BRPI1012128A2 (pt) composições contendo berberina ou seus análogos para tratamento de rosácea ou distúrbios de pele relacionados com face vermelha.
BR112013015816A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina e uso de uma construção de dna
BR112013012309A2 (pt) composto, composição, métodos de tratamento e usos de um composto
PT2236149E (pt) Composição medicinal para o tratamento de doenças infeciosas respiratórias
BRPI1014488A2 (pt) composições adequadas para o tratamento tópico de infecções fúngicas da pele e das unhas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]